Entera Bio (ENTX) Common Equity (2017 - 2026)
Entera Bio's (ENTX) quarterly Common Equity came in at $10.7 million in Q1 2026, down 44.85% YoY from $19.4 million in Q1 2025, and down 18.43% on a QoQ basis from $13.1 million in Q4 2025.
Entera Bio (ENTX) Common Equity (2017 - 2026) Analysis & Trends
Entera Bio (ENTX) has 10 years of Common Equity data on file, last reported at $10.7 million in Q1 2026.
- Quarterly Common Equity fell 44.85% year-over-year to $10.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.7 million (down 44.85% YoY) and the FY2025 annual result came in at $13.1 million, up 62.14% from the prior year.
- Common Equity slipped to $10.7 million in Q1 2026, from $13.1 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $19.7 million in Q1 2022 to a low of $6.2 million in Q3 2023.
- A 5-year average of $12.1 million and a median of $10.7 million in 2026 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2023 — Common Equity sank 56.43% — and 2025, when it soared 136.11%.
- Tracing ENTX's Common Equity over 5 years: stood at $11.8 million in 2022, then declined by 11.64% to $10.4 million in 2023, then slipped by 22.2% to $8.1 million in 2024, then soared by 62.14% to $13.1 million in 2025, then fell by 18.43% to $10.7 million in 2026.
- The last three Common Equity figures came in at $10.7 million (Q1 2026), $13.1 million (Q4 2025), and $15.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.24 Bn | 131.39 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.01 Bn | 78.02 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.61 Bn | 60.42 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.92 Bn | 51.78 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.77 Bn | 9.38 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 9.79 Bn |
| 10 | Entera Bio | 166.42 Mn | 155.11 Mn | - | 7.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.27 Mn |
| Mar 31, 2026 | 10.69 Mn |
| Dec 31, 2025 | 13.10 Mn |
| Sep 30, 2025 | 15.23 Mn |
| Jun 30, 2025 | 17.26 Mn |
| Mar 31, 2025 | 19.38 Mn |
| Dec 31, 2024 | 8.08 Mn |
| Sep 30, 2024 | 6.45 Mn |
| Jun 30, 2024 | 8.53 Mn |
| Mar 31, 2024 | 8.86 Mn |
| Dec 31, 2023 | 10.39 Mn |
| Sep 30, 2023 | 6.24 Mn |
| Jun 30, 2023 | 8.23 Mn |
| Mar 31, 2023 | 10.08 Mn |
| Dec 31, 2022 | 11.75 Mn |
| Sep 30, 2022 | 14.31 Mn |
| Jun 30, 2022 | 17.27 Mn |
| Mar 31, 2022 | 19.75 Mn |
| Dec 31, 2021 | 22.57 Mn |
| Sep 30, 2021 | 26.28 Mn |